FierceBiotechOriginal article
{"a":[{"_":"AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond","$":{"href":"/biotech/ausperbio-adds-120m-advance-hepatitis-b-therapy-through-ph3-and-commercialization","hreflang":"en"}}]}
Positive
AI Analysis
Summary
AusperBio Therapeutics raised $120 million in Series C funding to advance its oligonucleotide therapy for chronic hepatitis B through Phase 3 testing and commercialization.
Clinical Trial Data
Phase
Phase 3
Importance:6/10
Sentiment:
0.70
FinancingSeries COligonucleotideHepatitis BPhase 3
Read the original article
Published by FierceBiotech on August 28, 2026 10:30 AM
